Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Newer atypical antipsychotic drugs such as risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole that have been modelled on the prototype agent clozapine and developed since the 1990 s are now referred to as second-generation antipsychotic drugs (SGAs). It has been proposed that the interaction between serotonin (5-HT) and dopamine systems may play a critical role in the mechanism of action of atypical antipsychotic drugs because a relatively potent blockade of 5-HT(2A) receptors coupled with the weaker antagonism of the dopamine D(2) receptors is found to be the only pharmacological feature which most atypical antipsychotic drugs have in common. This so-called 'serotonin-dopamine hypothesis' has become a useful model for developing new SGAs to achieve superior antipsychotic efficacy with a lower incidence of extrapyramidal side effects compared to those with first-generation antipsychotic drugs (FGAs) such as haloperidol and chlorpromazine, although it has not been validated yet. In contrast, it has been proposed as the alternative 'fast-off' theory according to which atypical profile of SGAs can be determined by the loose D(2)-binding kinetics alone, while the blockade of the 5-HT(2A) receptor may be neither necessary nor sufficient. This chapter reviews the current issues on the serotonin-dopamine hypothesis together with further advances in research on the role of 5-HT receptor subtypes in the mechanism of action for SGAs. In particular, SGA-induced dopamine release in the prefrontal cortex, possibly through the functional activation of 5-HT(1A) receptors by 5-HT(2A) and D(2) receptor-mediated interaction, has been thought to be the basis for the neurocognitive effects of these drugs on schizophrenia. Thus, the novel antipsychotic aripiprazole may not only be a simply partial D(2) agonist but also a significant 5-HT(1A) agonist and 5-HT(2A) antagonist. These complex properties of antipsychotic aripiprazole may contribute to dopaminergic activation of the local circuitry in the prefrontal cortex of schizophrenic patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, quetiapine, but not olanzapine, may increase DA levels [39], preferentially in the NAc shell [40], with some data [41] suggesting as well a quetiapine-associated enhancement of cocaine reinforcing potency.”
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062 · cited 1×
“Proposal of the theory corresponded to the same time that some clinical studies began to suggest comparative effects of SGAs versus low-dose or low-potent FGAs with regard to clinical efficacy ( Geddes and Harrison, 2000; Davis et al., 2003; Leucht et al., 2003; Moncrieff, 2003).”
ResultA Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Cited by
Shin, H.-W., & Chung, S. J. (2012) · Journal of Clinical Neurology · doi:10.3988/jcn.2012.8.1.15 · Cited by 354
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 327
“These novel antipsychotics, now referred to as second-generation antipsychotics (SGAs), have been modeled on the prototype drug clozapine [2].”
BackgroundThe role of dopamine in bipolar disorder
Cousins, D. A., Butts, K., & Young, A. H. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00760.x · Cited by 291
Brain serotonergic circuitries
Charnay, Y., & Leger, L. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.4/ycharnay · Cited by 210
Molecular and cellular analysis of human histamine receptor subtypes
Seifert, R., Strasser, A., Schneider, E. H., Neumann, D., Dove, S., & Buschauer, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.11.001 · Cited by 168
Metadata
- Authors
- KUROKI, T., NAGAO, N., & NAKAHARA, T.
- Affiliations
- Hizen Psychiatric Center (JP)
- Corresponding author
- KUROKI, T
- ORCID
- NAKAHARA, T
- Venue
- Progress in brain research
- Publisher
- Elsevier
- Published
- 2008
- Volume
- 172
- Pages
- 199-212
- ISSN
- 0079-6123 (ISSN-L)
- OpenAlex
- W1495797590
- Cited by
- 146
- References
- 85
- Citations by year
- 2025: 8 · 2024: 7 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 10 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 5 · 2014: 13 · 2013: 8 · 2012: 15
- FWCI
- 45.16
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Progress in brain research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- atypical antipsychotics, 5-HT2A receptor antagonism, dopamine D2 receptor antagonism, 5-HT1A receptor, aripiprazole, neurocognitive effects, schizophrenia, extrapyramidal symptoms, mechanism of action
- MeSH terms
- Animals, Dopamine, Humans, Receptors, Dopamine, Receptors, Serotonin, Schizophrenia, Serotonin, Serotonin Antagonists, Antipsychotic Agents, Prefrontal Cortex, Dopamine Antagonists, Protein Isoforms, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. https://app.cochat.ai/papers/10.1016/s0079-6123(08)00910-2
- The paper
- KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008). Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Progress in brain research. https://doi.org/10.1016/s0079-6123(08)00910-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.